Prescription Drugs · Rare Disease Therapeutics
Vertex Pharmaceuticals revenue, results and funding
Vertex Pharmaceuticals filed revenue of $12B for 2025.
Data updated Nov 19, 2026 · Back to the company report
$12BRevenue, 2025
$4BNet income, 2025
VRTXNasdaq
Results by year
| Year | Revenue | Net income | Total assets | LANG_CR_S_M_TAX_PAID | LANG_CR_S_M_TAX_EXPENSE | LANG_CR_S_M_BUYBACKS | LANG_CR_S_M_CAPEX | LANG_CR_S_M_SBC | LANG_CR_S_M_RND | LANG_CR_S_M_OPERATING_INCOME | LANG_CR_S_M_CASH | LANG_CR_S_M_ACQUISITIONS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | $12B | $4B | $25.6B | $1.6B | $690M | $2B | $437.6M | $685.9M | $3.9B | $4.2B | $5.1B | – |
| 2024 | $11B | −$535.6M | $22.5B | $1.1B | $784.1M | $1.2B | $297.7M | $698.5M | $3.6B | −$232.9M | $4.6B | $0 |
| 2023 | $9.9B | $3.6B | $22.7B | $1.7B | $760.2M | $427.6M | $200.4M | $581.2M | $3.2B | $3.8B | $10.4B | $0 |
| 2022 | $8.9B | $3.3B | $18.2B | $1.1B | $910.4M | $0 | $204.7M | $491.3M | $2.5B | $4.3B | $10.5B | $295.9M |
| 2021 | $7.6B | $2.3B | $13.4B | $476.3M | $388.3M | $1.4B | $235M | $441.4M | $3.1B | $2.8B | $6.8B | $0 |
| 2020 | $6.2B | $2.7B | $11.8B | $191.8M | $405.2M | $539.1M | $259.8M | $429.5M | $1.8B | $2.9B | $6B | $0 |
| 2019 | $4.2B | $1.2B | $8.3B | $24.7M | $218.1M | $186M | $75.4M | $360.5M | $1.8B | $1.2B | $3.1B | $1.2B |
| 2018 | $3B | $2.1B | $6.3B | $12.4M | −$1.5B | $350M | $95.4M | $325M | $1.4B | $635.2M | $2.7B | $0 |
| 2017 | $2.5B | $263.5M | $3.6B | $6.4M | −$107.3M | $0 | $99.4M | $293.2M | $1.3B | $123.2M | $1.7B | $0 |
| 2016 | $1.7B | −$112.1M | $2.9B | −$2.6M | $16.7M | $0 | $56.6M | $240.6M | $1B | $9.9M | $1.2B | – |
| 2015 | $1B | −$556.3M | $2.5B | $1.8M | $30.4M | – | $45.3M | $231M | $995.9M | −$466.9M | $714.8M | – |
| 2014 | $580.4M | −$738.6M | $2.3B | $1.2M | $7M | – | $51.2M | $177.5M | $855.5M | −$692.4M | $625.3M | – |
| 2013 | $1.2B | −$445M | $2.3B | $2.8M | −$122.4M | – | $51.4M | $127.3M | $882.1M | −$610M | $569.3M | – |
| 2012 | $1.5B | −$107M | $2.8B | $9.3M | −$275k | – | $71.1M | $114.3M | $765.9M | $46.7M | $489.4M | – |
| 2011 | $1.4B | $29.6M | $2.2B | $0 | $19.3M | – | $34.6M | $118.2M | $707.7M | $113.8M | $475.3M | – |
Sources: SEC
How to cite
Vertex Pharmaceuticals, Financials. Alion, Nov 19, 2026. https://alion.io/company/vrtx/financials
